Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Investor Presentation (June 2019)
17 slides from Alterity Therapeutics's investor presentation, Jun 4, 2019
Slide 1: Investor Presentation June 2019
Investor Presentation (ASX:ATH) June 2019 Mr Geoffrey Kempler CEO and Chairman
Slide 2: Forward Looking Statements
This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expectations or
Slide 3: Alterity developing first-in-class therapies for neurodegenerative diseases
Alterity is developing first - in - class therapies to treat neurodegenerative diseases. Our lead drug candidate, PBT434, has demonstrated pre - clinical evidence as a first - in - class therapy for the treatment of Parkinsonian disorders and has had positive initial data in its Phase 1 clinical pro
Slide 4: Investment Proposition
INVESTMENT PROPOSITION ▪ Well - funded clinical stage drug development company following up to $44M strategic investment led by Life Biosciences LLC allowing accelerated and focused clinical development ▪ Strong and highly experienced board and management team with significant R&D and commercialisat
Slide 5: Strategic Investment
STRATEGIC INVESTMENT ▪ Strategic lead investor in a capital raise up to of approx. A$44 million ▪ The funding will accelerate the Company’s drug development programs ▪ Life Biosciences is a private US biopharmaceutical company focused on the development of novel therapies, technologies and drugs to
Slide 6: Therapeutic Focus
Therapeutic Focus
Slide 7: Parkinsonian disorders represent a substantial unmet medical need
▪ Parkinsonism is a general term for a group of symptoms in Parkinson's disease such as slowness of movement, stiffness and tremor ▪ Parkinsonian disorders include idiopathic Parkinson disease (PD) and atypical forms such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and co
Slide 8: Multiple System Atrophy (MSA)
▪ MSA is a rapidly progressive neurodegenerative disorder leading to severe disability and impairment in quality of life ▪ Sporadic (not inherited), typically presents in 50s to 60s ▪ Orphan disease: Prevalence 5 per 100,000 in the U.S. ▪ Patients have a variable combination of ▪ Parkinsonism, whi
Slide 9: FDA Orphan Designation for MSA
▪ January 2019, US Food and Drug Administration (FDA) granted Orphan Drug Designation for PBT434 for the treatment of MSA ▪ Orphan Drug designation entitles Alterity to seven years of market exclusivity for the use of PBT434 in the treatment of MSA and qualifies the sponsor of the drug for various d
Slide 10: Phase 1 Clinical Trial Program Advancing
▪ Single - and Multiple - Ascending Dose study to be completed Q2’19 ▪ Recruited healthy adult and elderly volunteers ▪ Primary goal is to evaluate the safety and tolerability of PBT434 ▪ Secondary goals include assessing pharmacokinetic measures to understand how PBT434 is absorbed and metabolized
Slide 11: Therapeutic Strategy
▪ Alpha ( α ) - synuclein is an intracellular protein critical for neurotransmission α - synuclein accumulates and aggregates in many neurodegenerative diseases and is implicated in pathology ▪ PBT434 blocks α - synuclein accumulation and aggregation, preserves neurons and improves function in anima
Slide 12: Validation of α-Synuclein as Disease Target
▪ α - Synuclein is critical for normal function of neurons and for neurotransmission ▪ α - Synuclein activity is disrupted in Parkinsonian diseases ▪ Pharmaceutical companies and research organisations recognize α - Synuclein as a promising disease target for Parkinsonian diseases VALIDATION OF α -
Slide 13: Market Opportunity and Company Information
Market Opportunity and Company Information
Slide 14: Commercial Opportunity
14 I 3 STRATEGY PARTNERS CONFIDENTIAL COMMERCIAL OPPORTUNITY *Does not include spontaneous use in PD or regions outside of Australia Severely debilitating, fatal illnesses with no current treatments are ripe for new entrants targeting what may be the actual cause of the disease. SUBSTANTIAL UNMET NE
Slide 15: Corporate Overview
Capital Structure Name Position Geoffrey Kempler CEO & Chairman Lawrence Gozlan Non - Executive Director Peter Marks Non - Executive Director Dr David Sinclair Non - Executive Director Tristan Edwards Non - Executive Director Brian Meltzer Non - Executive Director Board Management Team CORPORATE OVE
Slide 16: Investment Summary
INVESTMENT SUMMARY • Proven track record in taking new drugs through to market. Team responsible for 3 new drugs approved by FDA • Lead drug candidate PBT434 has the potential as a disease modifying treatment • Phase 1 clinical trial program almost completed. Results indicate PBT434 crosses the bloo
Slide 17: Contact
Contact Geoffrey Kempler IR@alteritytherapeutics.com Tel: +61 3 9349 4906
Alterity Therapeutics — Investor Presentation (June 2019) on 6ix